
    
      This is a multicenter, open-label, Phase 1/2 study to evaluate the safety, tolerability, PK,
      immunogenicity, and antitumor activity of MEDI0680 in combination with durvalumab or
      nivolumab monotherapy in adult immunotherapy-na√Øve subjects with selected advanced
      malignancies.
    
  